Keyword: Ablynx

Ablynx CMO Robert Zeldin is moving to Acceleron, to take over for longtime CMO Matthew Sherman, as it begins to get phase 3 data on luspatercept.

Ex-Millennium chief named CEO of Lundbeck; Ablynx's CMO to take post at Acceleron; and PredictImmune appoints new CEO.

Sanofi says its GLP-1 drug SAR425899 is undertaking new tests to try to get around dosing issues that is causing GI problems.

The $400 million deal gives Novo worldwide rights to an epigenetic treatment of the disease that is closing in on the start of a phase 2 trial.

The setback tarnishes one of the drugs Sanofi is set to acquire through its €3.9 billion takeover of Ablynx.

Sanofi’s €45-a-share cash bid enabled it to leapfrog Novo Nordisk in the race to buy Ablynx and land its second big-ticket takeover of the month. 

NICE leader joined ABPI; Heptares co-founder will lead Merck’s new London center; Sanofi named a business transformation head.

Van Herk Investments thinks Novo’s recent offer was too low, but it will encourage Ablynx to enter talks if a sufficiently sweetened bid is received.

Last year, a quiet J.P. Morgan Healthcare Conference meant few deals, few major updates. That set the tone for much of the year on the M&A front.